Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: veelken h. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Vanishing ulnae: symmetrical diffuse large B-cell lymphoma.
Roukens A, Vlasveld T, Veelken H, Kersting S. Roukens A, et al. Among authors: veelken h. Lancet. 2013 Dec 7;382(9908):e40. doi: 10.1016/S0140-6736(13)60144-0. Epub 2013 Jun 7. Lancet. 2013. PMID: 23746923 No abstract available.
Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Eefting M, von dem Borne PA, de Wreede LC, Halkes CJ, Kersting S, Marijt EW, Veelken H, Falkenburg JF. Eefting M, et al. Among authors: veelken h. Haematologica. 2014 Apr;99(4):751-8. doi: 10.3324/haematol.2013.089565. Epub 2013 Nov 15. Haematologica. 2014. PMID: 24241493 Free PMC article.
Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire.
Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V. Xavier E, et al. Among authors: veelken h. Biol Blood Marrow Transplant. 2015 Aug;21(8):1515-23. doi: 10.1016/j.bbmt.2015.04.026. Epub 2015 May 7. Biol Blood Marrow Transplant. 2015. PMID: 25958294 Free article.
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. Schrader AMR, et al. Among authors: veelken h. Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. Blood. 2018. PMID: 29514783 Free article. No abstract available.
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ. Löwenberg B, et al. Among authors: veelken h. Blood Adv. 2021 Feb 23;5(4):1110-1121. doi: 10.1182/bloodadvances.2020003855. Blood Adv. 2021. PMID: 33616652 Free PMC article. Clinical Trial.
Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL, van Eijk R, Böhringer S, van Wezel T, Raghoo R, Ruano D, Jansen PM, Briaire-de Bruijn I, de Groot FA, Kleiverda K, Te Boome L, Terpstra V, Levenga H, Nicolae A, Posthuma EFM, Focke-Snieders I, Hardi L, den Hartog WCE, Bohmer LH, Hogendoorn PCW, van den Berg A, Diepstra A, Nijland M, Lugtenburg PJ, Kersten MJ, Pals ST, Veelken H, Bovée JVMG, Cleven AHG, Vermaat JSP. de Groen RAL, et al. Among authors: veelken h. Blood Adv. 2021 Oct 12;5(19):3760-3775. doi: 10.1182/bloodadvances.2021005215. Blood Adv. 2021. PMID: 34478526 Free PMC article.
Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.
Hengeveld PJ, Veelken H, van Bergen CAM, Quinten E, Vervoordeldonk MYL, Ismailzada W, Barendse RS, Dubois JMN, van Oers MHJ, Geisler CH, Kater AP, Westerweel PE, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: veelken h. Leukemia. 2023 Sep;37(9):1929-1932. doi: 10.1038/s41375-023-01975-0. Epub 2023 Jul 21. Leukemia. 2023. PMID: 37479761 Free PMC article. No abstract available.
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.
Eefting M, Halkes CJ, de Wreede LC, van Pelt CM, Kersting S, Marijt EW, von dem Borne PA, Willemze R, Veelken H, Falkenburg JH. Eefting M, et al. Among authors: veelken h. Bone Marrow Transplant. 2014 Feb;49(2):287-91. doi: 10.1038/bmt.2013.111. Epub 2013 Aug 12. Bone Marrow Transplant. 2014. PMID: 23933760
Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH. Eefting M, et al. Among authors: veelken h. Haematologica. 2016 Apr;101(4):506-14. doi: 10.3324/haematol.2015.136846. Epub 2016 Jan 22. Haematologica. 2016. PMID: 26802054 Free PMC article.
182 results